Our study demonstrated similar or adequate psychometric properties of the French version of the FSFI compared to the original English version.

might not be limited to a maximum treatment area (e.g. 5% imiquimod is limited to 25 cm 2 ) and could be an attractive option

No abstract

Additional Supporting Information may be found online in the supporting information tab for this article. FIGURE S1The chemotaxis of T cells to recombinant CTACK. PBL that had migrated were labelled with florescent antibodies to T-cell marker CD3, memory cell marker CD45RO and "skin-homing" marker CLA. % migration is the normalised chemotaxis of (a) CD3+CD45RO+ cells or patients, 5 (22.7%) harboured a BRAF mutation, which was much higher than the rate of 5% reported in the literature. One patient, who was tested negative on the primary melanoma, had a NRAS mutation in a cutaneous metastasis. Our data provide a rationale for prospective and repeated mutations testing in female lower genital tract melanomas. | BACKGROUNDIn the past few years, several studies attempting to identify mutations in melanomas have opened the door for targeted therapies with the discovery of BRAF, NRAS and KIT mutations. When focusing on melanomas of the female lower genital tract, differences with cutaneous ones were observed concerning prognosis, treatment and also probably the pattern of mutations. Indeed, some recent studies suggest that KIT mutations are more common in vulvar melanomas and that BRAF mutations are less frequent in vulvar and vaginal melanomas than in cutaneous ones. [1][2][3][4][5][6] | QUESTION ADDRESSEDBecause available data on BRAF, NRAS and KIT mutations are scarce in patients with vulvar and vaginal melanomas and are associated with important therapeutic issues, we investigated their prevalence in a cohort of patients with female lower genital tract melanomas seen in our skin cancer unit.

No abstract